Spasticity Post-Spinal Cord Injury (Investigational Adjunct)
Investigational adjunct for muscular spasticity after SCI; no clinical study identified; baclofen (oral or intrathecal) and physiotherapy remain primary.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for spasticity after spinal cord injury. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- What evidence exists?
- Tier C (investigational). No clinical study of leech therapy for spasticity after spinal cord injury was identified in PubMed or Europe PMC. Evidence-based first-line management is structured physical and occupational therapy with stretching, oral antispasmodics (baclofen, tizanidine, dantrolene), and for refractory spasticity intrathecal baclofen pump, botulinum toxin injection, or selective dorsal rhizotomy. Triggers (UTI, pressure injury, constipation) must be addressed first.
- Main risks
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Autonomic dysreflexia in patients with injuries at T6 or above — sessions can trigger dangerous blood pressure surges
- Risk of pressure injury at bite sites in patients with sensory impairment
- Who should not consider this
- Patients with spinal cord injury at T6 or above without a clear autonomic dysreflexia monitoring plan
- Patients with active UTI, pressure injury, constipation, or other spasticity triggers (treat those first)
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
- People with hemophilia or any other inherited bleeding disorder
- Patients with anemia
- People with an active infection at the planned application site
- Patients who are pregnant (leech therapy is not done during pregnancy) or breastfeeding (discuss it with your doctor)
- What to ask your clinician
- Has a recent UTI, pressure injury, ingrown toenail, or constipation episode been ruled out as the spasticity trigger?
- Am I on optimal oral antispasmodic doses?
- Have intrathecal baclofen, botulinum toxin, or surgical options been discussed?
- What is the autonomic dysreflexia monitoring plan during and after sessions?
- How will sensory loss affect bite-site monitoring for pressure or infection?
- What is the published evidence in spinal cord injury spasticity specifically?
- When to seek urgent care
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Sudden severe headache, sweating above the level of injury, slow heart rate, severe high blood pressure (autonomic dysreflexia — emergency)
- Spread of redness or new wound at a numb area
What this does NOT mean
- It does not mean leech therapy is FDA-cleared for spasticity — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace structured PT/OT, antispasmodic medication, or intrathecal baclofen for severe cases.
- It does not modify the underlying spinal cord injury.
- It does not address spasticity triggers (UTI, pressure injury, bowel issues) — those must be treated separately.
- No clinical study of leech therapy in people with spinal cord injury was identified in PubMed or Europe PMC.
Safety cross-references
Clinical Profile
- Category
- Neurological
- ICD-10
- G82.20, G82.21, G82.22, G81.10
- Safety tier
- High
Evidence Summary
Spasticity affects a large majority of patients with spinal cord injury and is managed per Consortium for Spinal Cord Medicine guidelines with stretching, positioning, oral antispastic agents (baclofen, tizanidine), botulinum toxin for focal spasticity, and intrathecal baclofen for severe diffuse spasticity. No clinical study or case report of leech therapy for post-SCI spasticity was identified in PubMed, Europe PMC, ClinicalTrials.gov or the Baskova and Isakhanyan 2004 monograph; use is investigational only. Any peripheral tone reduction is speculative, and the cortical and spinal reflex contributions that drive spasticity would not be addressed by local leech application.
What the books describe
Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.
- Baskova and Isakhanyan do not write about spasticity after spinal cord injury in adults; closest to the topic is their paragraph about children with spastic diplegia of the lower limbs (Little syndrome)[B1].
- According to the authors’ description, in 5 children aged 3–6 with this diagnosis, positive changes appeared in all cases by the third month — a decrease in the spasticity of the limb muscles[B1].
- The description is very brief: it is not clear from the text how the children were treated, what and how spasticity was assessed, or whether there was a comparison group; in the reference list the work is titled “Treatment of childhood cerebral palsies by the method of hirudotherapy (Preliminary report)”[B1].
- Michalsen et al. name spastic conditions only in Bottenberg’s list of general indications in the historical overview and themselves remark that the plethora of indications at the time was still too broad; they do not write about spasticity, paralysis or spinal cord injury in the clinical chapters[B3].
- Among the contraindications, Baskova and Isakhanyan name taking anticoagulants, low blood pressure and anemia; Flecken and Michalsen also name wound-healing disorders: in localized areas of poor healing, leeches must not be applied directly to the affected area[B1][B3].
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Active deep vein thrombosis (acute phase)
- Critical limb ischemia (ABI <0.4)
- Pressure injuries at proposed treatment sites
- Autonomic dysreflexia (T6 or above SCI) without prophylaxis
- Anticoagulation for venous thromboembolism prophylaxis
- Concurrent botulinum toxin injection within 2 weeks
Related Conditions
Post-Stroke Hemiplegia (Investigational Adjunct)
Investigational adjunct to physical/occupational therapy in chronic post-stroke hemiplegia; no RCT support; not for acute stroke care.
Phantom Limb Pain (Investigational)
Highly investigational adjunct for chronic phantom limb pain; no clinical study identified; mirror therapy and gabapentinoids remain primary.
Complex Regional Pain Syndrome (Type I, Investigational)
Highly investigational adjunct for CRPS Type I; one case report and no controlled study identified; multidisciplinary pain management and physiotherapy remain primary.
Cervical Radiculopathy
Investigational use for cervical radiculopathy; no verifiable published trial specific to this indication.
References
- [B1]
Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]
Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.
- [B3]
Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy
ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.
The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.